News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
石藥(01093.HK)注射用紫杉醇獲批上市
石藥(01093.HK)公布，集團開發的注射用紫杉醇(白蛋白結合型)(II)(100mg)已獲得國家藥品監督管理局批准上市，為全球首個速溶白蛋白結合型紫杉醇制劑。該產品是集團自主研發的創新型抗腫瘤納米製劑，採用了創新的處方和製備工藝，相關專利已在中美歐等主要國家獲得授權。其適應症為聯合化療失敗的轉移性乳腺癌或輔助化療後6個月內復發的乳腺癌。(ha/a)~阿思...
Reset
Send
The window will close in 5 seconds
石藥(01093.HK)注射用紫杉醇獲批上市
Close
Recommend
3
Positive
10
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

石藥(01093.HK)  -0.290 (-3.946%)    Short selling $38.06M; Ratio 17.699%   公布，集團開發的注射用紫杉醇(白蛋白結合型)(II)(100mg)已獲得國家藥品監督管理局批准上市，為全球首個速溶白蛋白結合型紫杉醇制劑。

該產品是集團自主研發的創新型抗腫瘤納米製劑，採用了創新的處方和製備工藝，相關專利已在中美歐等主要國家獲得授權。其適應症為聯合化療失敗的轉移性乳腺癌或輔助化療後6個月內復發的乳腺癌。(ha/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-16 12:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.